Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
23
ATHE Quote, Financials, Valuation and Earnings
Last price:
$3.32
Seasonality move
:
4.13%
Day range:
$3.31 - $3.47
52-week range:
$1.90 - $7.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.58x
P/B ratio:
16.21x
Volume:
5.6K
Avg. volume:
16.3K
1-year change:
82.47%
Market cap:
$62.2M
Revenue:
--
EPS (TTM):
-$0.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
IMRN
Immuron Ltd.
|
-- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $16.49 |
|
MESO
Mesoblast Ltd.
|
$20.3M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATHE
Alterity Therapeutics Ltd.
|
$3.43 | $12.00 | $62.2M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$1.70 | $9.50 | $247.5M | -- | $0.00 | 0% | -- |
|
IMRN
Immuron Ltd.
|
$1.55 | -- | $8.9M | -- | $0.00 | 0% | 1.89x |
|
KZIA
Kazia Therapeutics Ltd.
|
$13.25 | $16.49 | $22.1M | -- | $0.00 | 0% | 598.69x |
|
MESO
Mesoblast Ltd.
|
$16.93 | $35.00 | $2.2B | -- | $0.00 | 0% | 118.82x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -1.575 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.640 | -- | -- |
|
IMRN
Immuron Ltd.
|
-- | 0.830 | -- | 5.77x |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 5.445 | 5.57% | 0.07x |
|
MESO
Mesoblast Ltd.
|
-- | 0.345 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMRN
Immuron Ltd.
|
-- | -- | -53.91% | -53.91% | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Alterity Therapeutics Ltd. vs. Competitors
-
Which has Higher Returns ATHE or IMMP?
Immutep Ltd. has a net margin of -- compared to Alterity Therapeutics Ltd.'s net margin of --. Alterity Therapeutics Ltd.'s return on equity of -- beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATHEAlterity Therapeutics Ltd.-- -- -- IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About ATHE or IMMP?
Alterity Therapeutics Ltd. has a consensus price target of $12.00, signalling upside risk potential of 249.85%. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 458.82%. Given that Immutep Ltd. has higher upside potential than Alterity Therapeutics Ltd., analysts believe Immutep Ltd. is more attractive than Alterity Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ATHEAlterity Therapeutics Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is ATHE or IMMP More Risky?
Alterity Therapeutics Ltd. has a beta of 0.023, which suggesting that the stock is 97.656% less volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.925, suggesting its more volatile than the S&P 500 by 92.469%.
-
Which is a Better Dividend Stock ATHE or IMMP?
Alterity Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alterity Therapeutics Ltd. pays -- of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATHE or IMMP?
Alterity Therapeutics Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Alterity Therapeutics Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Alterity Therapeutics Ltd.'s price-to-earnings ratio is -- while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alterity Therapeutics Ltd. is 3.58x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATHEAlterity Therapeutics Ltd.3.58x -- -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns ATHE or IMRN?
Immuron Ltd. has a net margin of -- compared to Alterity Therapeutics Ltd.'s net margin of --. Alterity Therapeutics Ltd.'s return on equity of -- beat Immuron Ltd.'s return on equity of -53.91%.
Company Gross Margin Earnings Per Share Invested Capital ATHEAlterity Therapeutics Ltd.-- -- -- IMRNImmuron Ltd.-- -- $6.4M -
What do Analysts Say About ATHE or IMRN?
Alterity Therapeutics Ltd. has a consensus price target of $12.00, signalling upside risk potential of 249.85%. On the other hand Immuron Ltd. has an analysts' consensus of -- which suggests that it could grow by 158.27%. Given that Alterity Therapeutics Ltd. has higher upside potential than Immuron Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Immuron Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ATHEAlterity Therapeutics Ltd.0 0 0 IMRNImmuron Ltd.0 0 0 -
Is ATHE or IMRN More Risky?
Alterity Therapeutics Ltd. has a beta of 0.023, which suggesting that the stock is 97.656% less volatile than S&P 500. In comparison Immuron Ltd. has a beta of 0.713, suggesting its less volatile than the S&P 500 by 28.672%.
-
Which is a Better Dividend Stock ATHE or IMRN?
Alterity Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuron Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alterity Therapeutics Ltd. pays -- of its earnings as a dividend. Immuron Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATHE or IMRN?
Alterity Therapeutics Ltd. quarterly revenues are --, which are smaller than Immuron Ltd. quarterly revenues of --. Alterity Therapeutics Ltd.'s net income of -- is lower than Immuron Ltd.'s net income of --. Notably, Alterity Therapeutics Ltd.'s price-to-earnings ratio is -- while Immuron Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alterity Therapeutics Ltd. is 3.58x versus 1.89x for Immuron Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATHEAlterity Therapeutics Ltd.3.58x -- -- -- IMRNImmuron Ltd.1.89x -- -- --
-
Which has Higher Returns ATHE or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Alterity Therapeutics Ltd.'s net margin of --. Alterity Therapeutics Ltd.'s return on equity of -- beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital ATHEAlterity Therapeutics Ltd.-- -- -- KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About ATHE or KZIA?
Alterity Therapeutics Ltd. has a consensus price target of $12.00, signalling upside risk potential of 249.85%. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $16.49 which suggests that it could grow by 24.49%. Given that Alterity Therapeutics Ltd. has higher upside potential than Kazia Therapeutics Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Kazia Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ATHEAlterity Therapeutics Ltd.0 0 0 KZIAKazia Therapeutics Ltd.0 0 0 -
Is ATHE or KZIA More Risky?
Alterity Therapeutics Ltd. has a beta of 0.023, which suggesting that the stock is 97.656% less volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.185%.
-
Which is a Better Dividend Stock ATHE or KZIA?
Alterity Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alterity Therapeutics Ltd. pays -- of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATHE or KZIA?
Alterity Therapeutics Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Alterity Therapeutics Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Alterity Therapeutics Ltd.'s price-to-earnings ratio is -- while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alterity Therapeutics Ltd. is 3.58x versus 598.69x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATHEAlterity Therapeutics Ltd.3.58x -- -- -- KZIAKazia Therapeutics Ltd.598.69x -- -- --
-
Which has Higher Returns ATHE or MESO?
Mesoblast Ltd. has a net margin of -- compared to Alterity Therapeutics Ltd.'s net margin of --. Alterity Therapeutics Ltd.'s return on equity of -- beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATHEAlterity Therapeutics Ltd.-- -- -- MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About ATHE or MESO?
Alterity Therapeutics Ltd. has a consensus price target of $12.00, signalling upside risk potential of 249.85%. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 106.73%. Given that Alterity Therapeutics Ltd. has higher upside potential than Mesoblast Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Mesoblast Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ATHEAlterity Therapeutics Ltd.0 0 0 MESOMesoblast Ltd.1 0 0 -
Is ATHE or MESO More Risky?
Alterity Therapeutics Ltd. has a beta of 0.023, which suggesting that the stock is 97.656% less volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.508%.
-
Which is a Better Dividend Stock ATHE or MESO?
Alterity Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alterity Therapeutics Ltd. pays -- of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATHE or MESO?
Alterity Therapeutics Ltd. quarterly revenues are --, which are smaller than Mesoblast Ltd. quarterly revenues of --. Alterity Therapeutics Ltd.'s net income of -- is lower than Mesoblast Ltd.'s net income of --. Notably, Alterity Therapeutics Ltd.'s price-to-earnings ratio is -- while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alterity Therapeutics Ltd. is 3.58x versus 118.82x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATHEAlterity Therapeutics Ltd.3.58x -- -- -- MESOMesoblast Ltd.118.82x -- -- --
-
Which has Higher Returns ATHE or PPCB?
has a net margin of -- compared to Alterity Therapeutics Ltd.'s net margin of --. Alterity Therapeutics Ltd.'s return on equity of -- beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATHEAlterity Therapeutics Ltd.-- -- -- PPCB-- -$0.00 -- -
What do Analysts Say About ATHE or PPCB?
Alterity Therapeutics Ltd. has a consensus price target of $12.00, signalling upside risk potential of 249.85%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Alterity Therapeutics Ltd. has higher upside potential than , analysts believe Alterity Therapeutics Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings ATHEAlterity Therapeutics Ltd.0 0 0 PPCB0 0 0 -
Is ATHE or PPCB More Risky?
Alterity Therapeutics Ltd. has a beta of 0.023, which suggesting that the stock is 97.656% less volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock ATHE or PPCB?
Alterity Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alterity Therapeutics Ltd. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATHE or PPCB?
Alterity Therapeutics Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Alterity Therapeutics Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Alterity Therapeutics Ltd.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alterity Therapeutics Ltd. is 3.58x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATHEAlterity Therapeutics Ltd.3.58x -- -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 5
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
